A Review on Autoimmune Bone Disease: Its challenges and Prospective Therapeutics

PROJECT REPORT

[In the partial fulfillment of the requirements for the degree of Bachelor of Pharmacy]

Submitted To

The Department of Pharmacy

Faculty of Health & Life Sciences

Daffodil International University

Submitted By

Farjana Islam Shikha

Student ID: 201-29-373

Department of Pharmacy

Faculty of Health & Life Sciences

Daffodil International University

……

April 2024

APPROVAL

This project paper, **"A Review on Autoimmune Bone Disease: Its challenges and Prospective Therapeutics",** submitted to the Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, has been accepted as satisfactory for the partial fulfillment of the requirements for the degree of Bachelor of Pharmacy and approved as to its style and contents.

BOARD OF EXAMINERS

……

Dr. Muniruddin Ahmed
Professor and Head
Department of Pharmacy
Faculty of Health & Life Sciences
Daffodil International University

…… Internal Examiner 1

…… . Internal Examiner 2

…… External Examiner 3

DECLARATION

I hereby declare that this project report, **"A Review on Autoimmune Bone Disease: Its challenges and Prospective Therapeutics"** is done by me under the supervision of Md. A.K. Azad Assistant Professor, I am declaring that this Project is my original work. I also declare that neither this project nor any part thereof has been submitted elsewhere for the award of Bachelor or any degree.

Supervised by

……..

Md. A.K. Azad

Assistant Professor

Department of Pharmacy

Faculty of Health & Life Sciences

Daffodil International University

Submitted By

Shikha

…….

Farjana Islam Shikha

Student ID: 201-29-373

Department of Pharmacy

Faculty of Health & Life Sciences

Daffodil International University

ACKNOWLEDGEMENT

I might want to communicate my profound applause to the All-powerful Allah who has given me the capacity to finish my undertaking work and the chance to concentrate in this subject.

I'm a lot of thankful to my honorable project supervisor Md. A.K. Azad Assistant Professor, Department of Pharmacy, Daffodil International University.

I would like to express my humble regards to Dr. Muniruddin Ahmed, Professor and Head, Department of Pharmacy, Daffodil International University.

I also wish to offer my respect to all of the teachers of Pharmacy Department, Daffodil International University and thankful to other members for their excellent cooperation with us.

Finally, I would like to express my gratitude towards my parents and other family members for their kind cooperation and encouragement which helped me in completion of this project.



My Parents,

The persons who always encourage me in every sphere of my life.

My teacher,

The persons who guided me in this process and the committee who kept me on track.

Abstract

Autoimmune bone diseases present unique challenges in both diagnosis and treatment, often resulting in debilitating consequences for patients. This study explores the complexities surrounding autoimmune bone diseases, including their etiology, pathogenesis, and clinical manifestations. An evaluation leads the inspection; about 35 publications from 2005-2023 and all work completed in Microsoft Word. Despite advancements in medical understanding, significant gaps remain in fully elucidating the underlying mechanisms driving these conditions. Furthermore, conventional therapeutic approaches often yield limited efficacy and may be accompanied by adverse effects. Consequently, there is an urgent need for innovative therapeutic strategies tailored to address the specific immunological dysregulation underlying autoimmune bone diseases. It's also discusses prospective therapeutics, including emerging biologic agents, targeted immunomodulatory therapies, and regenerative medicine approaches, which hold promise in revolutionizing the management of autoimmune bone diseases. However, the translation of these promising therapies from preclinical studies to clinical practice presents its own set of challenges, including safety concerns, optimal dosing regimens, and long-term efficacy. Therapeutic approach for autoimmune diseases include physical therapy, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying anti-inflammatory drugs (DMARDs), anticytokine therapies, inhibition of intracellular-signaling pathways, costimulation inhibition, biological inhibitors of T cell. Autoimmune bone diseases present diagnostic and treatment challenges due to their complexity and variability in symptoms, requiring comprehensive interdisciplinary approaches for effective management. In conclusion all though autoimmune disease is not curable. This challenges but it can be suppress by available therapeutic approach.

Contents

Chapter 1
Introduction

1. Introduction

Autoimmune bone diseases represent a diverse group of conditions characterized by dysregulation of the immune system, leading to inflammation and damage to bone tissue. These diseases pose significant challenges to patients and healthcare providers alike due to their complexity, heterogeneity, and often debilitating effects on skeletal health. However, advancements in our understanding of the underlying mechanisms driving autoimmune bone diseases have opened avenues for the development of prospective therapeutics aimed at managing symptoms, halting disease progression, and improving quality of life for affected individuals [1]. In recent years, autoimmune bone diseases have garnered increasing attention within the medical and scientific communities, driven by a growing recognition of their prevalence and impact on global health. Conditions such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and ankylosing spondylitis (AS) are among the most well-known autoimmune disorders affecting the skeletal system. However, there are also rare and less understood conditions, such as SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, and osteitis) and chronic recurrent multifocal osteomyelitis (CRMO), which present unique challenges in diagnosis and management [2]. One of the primary challenges in treating autoimmune bone diseases lies in their complex etiology, which involves a combination of genetic predisposition, environmental factors, and dysregulated immune responses. These diseases often manifest with diverse clinical presentations, ranging from joint pain and stiffness to bone deformities and systemic complications. Moreover, the progressive nature of many autoimmune bone diseases can lead to irreversible damage, functional impairment, and increased risk of comorbidities such as osteoporosis and cardiovascular disease [3]. Traditional approaches to managing autoimmune bone diseases have primarily focused on symptomatic relief and immunosuppression to control inflammation. While these strategies have been effective for many patients, they are often associated with significant side effects and may not adequately address the underlying immune dysregulation driving disease progression. Furthermore, a subset of patients may be refractory to conventional therapies or experience disease flares despite treatment optimization, highlighting the need for alternative therapeutic modalities [4]. In recent years, there has been a surge of interest in the development of targeted biologic agents and immunomodulatory therapies for autoimmune

bone diseases. These novel interventions aim to selectively inhibit key mediators of inflammation, restore immune homeostasis, and preserve bone integrity. From monoclonal antibodies targeting pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) to small molecule inhibitors of intracellular signaling pathways, a diverse array of prospective therapeutics are being investigated in preclinical and clinical settings [5]. In this review, we will explore the challenges inherent in diagnosing and managing autoimmune bone diseases, with a focus on their diverse clinical manifestations, underlying pathophysiology, and impact on patient outcomes. Additionally, we will discuss the current landscape of prospective therapeutics in development, highlighting emerging treatment modalities and ongoing clinical trials aimed at addressing the unmet needs of patients with these complex and often debilitating conditions [6]. By elucidating the complexities of autoimmune bone diseases and exploring the potential of innovative therapeutic approaches, we aim to provide insights that may ultimately improve outcomes and quality of life for affected individuals [7].

1.1 Etiology of Autoimmune Bone disease

Autoimmune bone diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and ankylosing spondylitis (AS), among others, are complex conditions with multifactorial etiologies. Here are some factors that contribute to the development of autoimmune bone diseases:

1. **Genetics**: There is a significant genetic component to autoimmune diseases, including those affecting the bones. Certain genes predispose individuals to develop autoimmune disorders. For example, specific human leukocyte antigen (HLA) genes have been associated with increased susceptibility to autoimmune bone diseases such as RA and AS [8].
2. **Immune system dysfunction**: In autoimmune diseases, the immune system mistakenly attacks the body's own tissues. In the case of autoimmune bone diseases, this immune dysregulation targets components of the musculoskeletal system, leading to inflammation and tissue damage in bones and joints.
3. **Environmental factors**: Environmental triggers, such as infections, smoking, and exposure to certain chemicals, may play a role in initiating or exacerbating autoimmune

bone diseases in genetically susceptible individuals. For example, smoking has been linked to an increased risk of developing RA [9].

4. **Hormonal influences**: Hormones, particularly estrogen, may influence the development and progression of autoimmune bone diseases. For instance, women are more likely to develop RA than men, and hormonal changes, such as those occurring during pregnancy and menopause, can affect disease activity.
5. **Microbiome**: Emerging research suggests that alterations in the composition of the gut microbiome may contribute to the development of autoimmune diseases, including those affecting the bones. Disruptions in the balance of gut bacteria can influence immune system function and promote inflammation, potentially contributing to autoimmune bone diseases.
6. **Epigenetics**: Epigenetic modifications, which affect gene expression without altering the underlying DNA sequence, may also play a role in the development of autoimmune bone diseases. Environmental factors and lifestyle choices can influence epigenetic changes, impacting immune function and disease susceptibility [10].
7. **Dysregulated cytokine production**: Cytokines are signaling molecules that regulate immune responses and inflammation. In autoimmune bone diseases, there is dysregulated production of cytokines, such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1), and interleukin-6 (IL-6), which contribute to inflammation and tissue damage in bones and joints.
8. **Autoantibodies**: Autoantibodies, antibodies that mistakenly target the body's own tissues, are characteristic features of many autoimmune diseases, including those affecting the bones. For example, rheumatoid factor and anti-cyclic citrullinated peptide (anti-CCP) antibodies are commonly found in individuals with RA [11].

Overall, autoimmune bone diseases result from a complex interplay of genetic, environmental, hormonal, immunological, and epigenetic factors. Further research is needed to fully understand the etiology of these conditions and develop more effective treatments.

1.2 Pathogenesis of Autoimmune Bone disease

Immune tolerance is breached in the pathophysiology of autoimmune disorders, albeit numerous pathways may generate this event. It is generally acknowledged that certain combinations of both genetic and environmental factors impact the growth of autoimmune diseases, as is associated with numerous illnesses. It is now clear that, even in the lack of sequencing mutations, alterations in DNA and DNA-protein structure may affect how genes are expressed [12]. This is known as the epigenetic phenomena, and the identification of the process regulating gene regulation has opened up a whole new field of study for the diagnosis and treatment of illnesses. The application of epigenetic approaches to regulate gene expression has demonstrated considerable promise in the creation of novel therapeutics for autoimmune disorders because of the wide range of cellular and molecular derangements associated with autoimmune conditions. Specifically, the diversity observed in the phenotypes of autoimmune disorders suggests that different people with the same autoimmune disease may have different triggers or different patho physiologies. Implemented [13].

1.3 Preventive action of Autoimmune Bone disease

Preventive measures for autoimmune bone diseases primarily revolve around managing the underlying autoimmune condition and promoting bone health. Here are some strategies that may help in preventing autoimmune bone diseases [14]:

1. **Manage the Underlying Autoimmune Condition**: Since autoimmune bone diseases are often secondary to autoimmune disorders such as rheumatoid arthritis, lupus, or ankylosing spondylitis, controlling the primary autoimmune condition is crucial. This may involve medications such as disease-modifying Antirheumatic drugs (DMARDs), biologics, or immunosuppressants, as prescribed by a rheumatologist or immunologist.
2. **Regular Medical Monitoring**: Regular check-ups with healthcare providers, including rheumatologists or orthopedic specialists, can help monitor the progression of autoimmune conditions and detect any signs of bone involvement early on [15].
3. **Medication Adherence**: Strict adherence to prescribed medications is essential to manage autoimmune conditions effectively and prevent complications such as bone damage.

4. **Lifestyle Modifications**: Adopting a healthy lifestyle can support overall bone health. This includes maintaining a balanced diet rich in calcium and vitamin D, engaging in weight-bearing exercises to strengthen bones, quitting smoking, limiting alcohol intake, and ensuring adequate rest and stress management.
5. **Bone Density Monitoring**: Regular bone density scans (DEXA scans) may be recommended, especially for individuals with autoimmune conditions known to affect bone health, to assess bone density and detect osteoporosis or osteopenia early [16].
6. **Calcium and Vitamin D Supplementation**: Depending on individual needs and dietary intake, supplementation with calcium and vitamin D may be advised, especially for those at higher risk of bone loss due to autoimmune conditions or medications used to treat them.
7. **Fall Prevention Strategies**: People with autoimmune bone diseases, particularly those with compromised bone strength, should take precautions to prevent falls, such as removing trip hazards at home, using assistive devices if necessary, and practicing balance exercises.
8. **Avoidance of Excessive Corticosteroids**: While corticosteroids are often used to manage autoimmune conditions, long-term use can lead to bone loss and osteoporosis. Whenever possible, healthcare providers may seek to minimize the dosage and duration of corticosteroid therapy or explore alternative treatments [17].
9. **Education and Awareness**: Patients should be educated about the potential impact of autoimmune conditions on bone health and the importance of adhering to treatment plans, lifestyle modifications, and preventive measures.
10. **Consultation with Specialists**: Collaborating with a multidisciplinary team of healthcare providers, including rheumatologists, orthopedic specialists, endocrinologists, and physical therapists, can ensure comprehensive management and prevention of complications associated with autoimmune bone diseases [18].

It's important to note that preventive strategies may vary depending on the specific autoimmune condition and individual health status. Therefore, individuals should work closely with their healthcare providers to develop a tailored approach to prevention and management.

1.4 Relation between Rheumatoid arthritis and autoimmunity

Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by inflammation of the joints, which leads to pain, stiffness, swelling, and eventually joint damage and deformity. The exact cause of RA is not fully understood, but it is believed to involve a combination of genetic, environmental, and immunological factors [19]. Autoimmunity is a condition where the body's immune system mistakenly attacks its own tissues, leading to inflammation and tissue damage. In the case of RA, the immune system targets the synovium, which is the lining of the membranes that surround the joints. This results in the production of autoantibodies, such as rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs), which contribute to the inflammatory process and joint damage.

Several factors contribute to the development of autoimmunity in RA:

Genetic predisposition: Certain genetic variations are associated with an increased risk of developing RA. For example, specific human leukocyte antigen (HLA) alleles, particularly the HLA-DRB1 gene, are strongly linked to RA susceptibility. However, having these genetic variants does not guarantee that a person will develop RA, indicating that environmental factors also play a significant role.

Environmental triggers: Environmental factors, such as smoking, infections, and hormonal changes, have been implicated in triggering or exacerbating RA. These factors may interact with genetic predisposition to initiate an abnormal immune response against self-antigens [20].

Dysregulation of the immune system: In RA, there is a dysregulation of the immune system, leading to the activation of immune cells, particularly T cells and B cells, and the production of inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1), and interleukin-6 (IL-6). These inflammatory mediators contribute to the destruction of joint tissues and the perpetuation of the autoimmune response.

Production of autoantibodies: Autoantibodies such as rheumatoid factor and ACPAs are produced by B cells and target self-antigens, such as citrullinated proteins, which are present in the synovium [21].

Chapter 2
Purpose of the study

2. Purpose of the study

This study aims to explore the challenges associated with autoimmune bone diseases and evaluate the prospective therapeutics that hold promise in addressing these challenges.

- **To identification of Challenges:** The study will delve into the various challenges encountered in the diagnosis and management of autoimmune bone diseases.
- **Mechanistic Insights:** By reviewing current literature and research findings, the study will elucidate the underlying immunological mechanisms contributing to autoimmune bone diseases.
- **To evaluation of Prospective Therapeutics:** The study will critically evaluate emerging therapeutic approaches for autoimmune bone diseases, including pharmacological agents, biologics, and immunomodulatory therapies.
- **Clinical Implications and Future Directions:** Based on the findings of this study, implications for clinical practice and future research directions will be discussed.

Chapter 3
Literature Review

3.1 Bone Loss Triggered by the Cytokine Network in Inflammatory Autoimmune Diseases

In vertebrates, reconstruction of bones is a lifetime procedure that depends on the proper ratio of osteoblast bone creation to osteoclast bone resorption. Inflammatory autoimmune illnesses like rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, and systemic lupus erythematosus are associated with bone loss and an increased risk of fractures. Patients with inflammatory autoimmune illnesses experience considerable bone loss as a result of the uncoupling of bone production and turnover caused by a network of inflammatory cytokines released during chronic inflammation. The involvement of the inflammatory cytokine network in the pathophysiological features and therapeutic developments in inflammatory autoimmune disorders are reviewed and discussed here [22].

3.2 Bone Marrow Transplantation for Autoimmune Diseases

BMT, or bone marrow transplantation, is increasingly showing promise as a therapy for autoimmune disease patients. We have previously discovered that systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), immune thrombocytic purpura, which insulin-dependent diabetes mellitus (IDDM), chronic glomerulonephritis, and some forms of non-insulin-dependent diabetes mellitus can all be treated with allogeneic BMT (not autologous BMT). On the other hand, we have discovered that transplanting partially purified hemopoietic stem cells (HSCs) or T-cell-depleted bone marrow cells from autoimmune-prone animals to normal mice induces autoimmune disorders in the transplants. Nevertheless, after autologous BMT, there have been instances of autoimmune disorders persisting or reoccurring quickly. In contrast, reports have indicated that autoimmune disorders like myasthenia gravis, IDDM, and Graves' disease can be adoptedly transferred from donors to recipients through allogeneic bone marrow transplantation. We have suggested that inflammatory illness is "a stem cell illness" in light of these observations. We have developed a novel purification technique for HSCs in order to elucidate the distinctions between normal and aberrant HSCs. We separated HSCs from autoimmune-prone and normal mice applying this technique, then we contrasted the two groups [23].

3.3 The multiple faces of autoimmune-mediated bone loss

Because it encourages the local breakdown of cartilage and the systemic and local breakdown of bone by osteoclasts, as well as inhibiting the production of new bone by osteoblasts, inflammation is known to disturb normal bone homeostasis and cause bone loss. It follows that inflammatory autoimmune illnesses frequently result in localized or widespread bone loss. The processes underlying autoimmune disease that affect the bone, nevertheless, are multifaceted and intricate. They encompass a spectrum of actions, from immune cells directly attacking bone and cartilage to indirect effects resulting from disruptions in the general regulation of bone regeneration. The present knowledge regarding the processes underlying autoimmune-mediated bone loss is reviewed in this overview in light of recent discoveries in two novel fields of study: integrative digestion (which has demonstrated the presence of neuroendocrine loops that regulate bone remodeling) and osteoimmunology, which examines the direct impact of immune cells on bone [24].

Chapter 4
Methodology

4.1 Data collection procedure

Look for books, conference proceedings, peer-reviewed journals, and legal guidelines pertaining to **"A Review on Autoimmune Bone Disease: Its challenges and Prospective Therapeutics"** To locate pertinent papers, reputable databases such as PubMed, Scopus, Google Scholar, and Research Gate have been utilized.

- It has been starting work for this in January 2024.
- Every effort has been made to gather as much information as possible by using search terms such as "Pathophysiology of Autoimmune Bone Disease," "Prevention of Autoimmune Bone Disease," "Management of Autoimmune Bone Disease," and "Etiology of Autoimmune Bone Disease". These terms were checked for potential exploits on educational bibliographic databases, web-based search engines, PubMed, Research Gate, Google Scholar, and Medline.
- An academic evaluation leads the inspection; about 35 publications are examined for this evaluation.
- In an effort to streamline the process, compiling all data from **2005 to 2023** and all work completed in Microsoft Word.
- Each assessment paper that was created was reviewed, and it got even more scholarly. The gathered information has finally been distilled.

4.2 Data analysis strategy

Data analysis is the methodical application of statistical and/or logical tools for describing and illustrating, condensing and summarizing, and evaluating data. Microsoft Excel was used to analyses the data.

Chapter 5
Results & Discussion

5.1 Autoimmune bone diseases challenges

Autoimmune bone diseases present significant challenges for both patients and healthcare providers due to their complexity and diverse manifestations. Some of the key challenges associated with autoimmune bone diseases include:

Diagnosis: Autoimmune bone diseases often present with nonspecific symptoms, making diagnosis challenging. This can lead to delays in treatment initiation and potentially irreversible damage to bone and other affected tissues [35].

Differential Diagnosis: Distinguishing between autoimmune bone diseases and other conditions with similar symptoms can be difficult. This requires careful consideration of clinical presentation, laboratory tests, imaging studies, and sometimes invasive procedures such as biopsies.

Disease Heterogeneity: Autoimmune bone diseases encompass a wide range of conditions, each with its own unique clinical features, underlying mechanisms, and treatment approaches. Managing this heterogeneity requires a tailored approach to patient care, which can be challenging in clinical practice.

Disease Progression: Autoimmune bone diseases often have unpredictable disease courses, with periods of remission and relapse. Predicting disease progression and identifying factors that may exacerbate or mitigate disease activity are important but challenging tasks [36].

Treatment Selection: Treatment options for autoimmune bone diseases include immunosuppressive medications, biologics, and targeted therapies. Selecting the most appropriate treatment for individual patients requires balancing efficacy, safety, and patient preferences, which can be challenging given the limited evidence base for some therapies and the potential for adverse effects.

Management of Complications: Autoimmune bone diseases can lead to various complications, including fractures, joint deformities, and systemic manifestations affecting other organs. Managing these complications requires a multidisciplinary approach involving rheumatologists, orthopedic surgeons, endocrinologists, and other specialists.

Patient Education and Support: Living with an autoimmune bone disease can have a significant impact on patients' quality of life, requiring ongoing education, support, and access to resources. Empowering patients to actively participate in their care and adhere to treatment regimens is crucial but can be challenging, especially given the chronic nature of these conditions [37].

Research and Innovation: Despite advances in understanding autoimmune bone diseases, many aspects of their pathogenesis, natural history, and optimal management remain poorly understood. Further research and innovation are needed to develop new diagnostic tools, biomarkers, and targeted therapies to improve outcomes for patients with these challenging conditions.

5.2 Therapeutic approach for autoimmune bone diseases

Autoimmune bone diseases are conditions where the body's immune system mistakenly attacks the bones, leading to inflammation, pain, and potentially serious complications. Some common autoimmune bone diseases include rheumatoid arthritis, lupus, and ankylosing spondylitis. The therapeutic approach for these conditions typically involves a combination of medications, lifestyle modifications, and sometimes surgical interventions. Here's a general overview of the therapeutic approach:

Medications:

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): These medications help reduce pain and inflammation associated with autoimmune bone diseases.

Disease-Modifying Antirheumatic Drugs (DMARDs): DMARDs like methotrexate, sulfasalazine, and hydroxychloroquine are commonly used to slow down the progression of autoimmune bone diseases and preserve joint function.

Biologic Response Modifiers: Biologics such as tumor necrosis factor (TNF) inhibitors (e.g., etanercept, adalimumab), interleukin inhibitors, and B-cell inhibitors target specific components of the immune system to reduce inflammation and halt disease progression.

Corticosteroids: These may be prescribed to quickly reduce inflammation during disease flares but are often used at low doses due to long-term side effects.

Bone-Strengthening Medications: In conditions like osteoporosis, medications such as bisphosphonates may be prescribed to prevent bone loss and reduce the risk of fractures.

Lifestyle Modifications:

Regular Exercise: Low-impact exercises such as swimming, cycling, and walking can help improve joint flexibility, strengthen muscles, and maintain bone health.

Balanced Diet: Consuming a diet rich in fruits, vegetables, whole grains, and lean proteins can help support overall health and may have anti-inflammatory effects.

Smoking Cessation: Smoking can exacerbate inflammation and increase the risk of complications in autoimmune diseases, so quitting smoking is strongly recommended.

Stress Management: Stress can worsen symptoms of autoimmune diseases, so techniques such as meditation, yoga, or deep breathing exercises may be beneficial.

Surgical Interventions:

In severe cases where joint damage is extensive and causing significant pain or disability, surgical interventions such as joint replacement surgery or joint fusion may be considered to restore function and alleviate pain.

Monitoring and Follow-up:

- Regular monitoring by healthcare providers is essential to assess disease activity, adjust medications as needed, and detect any potential complications early.
- Patient education about the disease, treatment options, and self-management strategies is crucial for empowering individuals to actively participate in their care and make informed decisions.

5.3 Vitamin D in Health

Vitamin D plays a crucial role in maintaining overall health and well-being. Here are some key aspects of its importance in health:

1. **Bone Health**: Vitamin D helps in the absorption of calcium and phosphorus, which are essential for maintaining strong and healthy bones. Without sufficient vitamin D, bones

can become brittle and weak, leading to conditions such as osteoporosis and rickets (in children).

2. **Immune Function**: Vitamin D is known to modulate the immune system, helping the body fight off infections and diseases. Adequate levels of vitamin D are associated with reduced risk of respiratory infections, autoimmune diseases, and other immune-related disorders.
3. **Mood Regulation**: Some studies suggest that vitamin D may play a role in regulating mood and preventing depression. Research has shown a correlation between low levels of vitamin D and an increased risk of depression and seasonal affective disorder (SAD) [25].
4. **Heart Health**: Vitamin D deficiency has been linked to an increased risk of cardiovascular diseases, including hypertension, heart attack, and stroke. Vitamin D may help regulate blood pressure, improve vascular function, and reduce inflammation, thereby promoting heart health.
5. **Cancer Prevention**: There is evidence suggesting that adequate levels of vitamin D may lower the risk of certain types of cancer, including colorectal, breast, and prostate cancer. Vitamin D is believed to inhibit the growth of cancer cells and promote their apoptosis (cell death).
6. **Muscle Function**: Vitamin D is important for muscle function and strength. It helps in the synthesis of proteins necessary for muscle contraction and may reduce the risk of falls and fractures in older adults by improving muscle function [26].
7. **Brain Health**: Some studies have suggested a potential link between vitamin D deficiency and cognitive decline, dementia, and Alzheimer's disease. Adequate levels of vitamin D may help maintain cognitive function and protect against age-related cognitive decline.
8. **Pregnancy and Infant Health**: Vitamin D is important during pregnancy for the development of the baby's bones and teeth. Maternal vitamin D deficiency has been associated with an increased risk of pre-eclampsia, gestational diabetes, and low birth weight. Adequate vitamin D intake during infancy is also crucial for optimal bone health and growth [27].

It's important to note that while vitamin D can be synthesized by the body through exposure to sunlight, many people have inadequate levels due to factors such as limited sun exposure, use of sunscreen, dark skin pigmentation, age, and certain medical conditions.

Therefore, it may be necessary for some individuals to obtain vitamin D from dietary sources or supplements to maintain optimal health. However, it's always recommended to consult with a healthcare professional before starting any supplementation regimen [28].

Vitamin D's function in the immune system. An illustration of the innate and adaptive immune processes' cells. The innate immune system's monocytes and macrophages produce pattern recognition receptors (PRR) with the value toll-like receptors (TLR) and react to pathogen-associated molecular patterns (PAMPs) like lipopolysaccharide (LPS). PAMP-PRR responses include using STAT 1 or 5, AP-1, NF-κB, or CEBP response components in order to induce production leading to higher levels of the vitamin D receptor (VDR) and the vitamin D-activating enzyme 1α-hydroxylase (CYP27B1). This enhances the ability of monocytes and macrophages to metabolize 25-hydroxyvitamin D3 (25-OHD3) into 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3), which subsequently engages in an interaction with VDR to modulate the functioning of genes through DNA vitamin D response components (VDRE) [29].

5.4 HSCT in rheumatic autoimmune disease

Since it was first used to treat leukemia more than 30 years ago, hematopoietic stem cell therapy (HSCT) has rapidly gained acceptance as an ordinary therapy for a variety of haemato-oncological conditions. However, its implementation in AD has long been impeded by worries that the procedure might not be practical or be too toxic for immunosuppressed patients with poor functioning and multiple organs suffering from the fundamental rheumatic illness. While there has been a steep learning process, it is now well established that HSCT is feasible in AD patients. Even accounting for the limitations of such investigations, certain trends regarding safety and effectiveness have been identified from prospective pilot trials and retrospectively database analysis [30]. More rigorous regimens were linked to increased treatment-related mortality but only marginally lower recurrence likelihood; however, more precise analyses are impossible due to variations in regimens, patient admission requirements, and outcome factors. Crucially, there has been a significant improvement in HSCT safety, as seen by the sharp decline in transplant-related mortality (TRM) among patients suffering from significant systemic sclerosis (SSc). In an additional evaluation of 65 patients, including the 41 previously mentioned,

the TRM decreased from 17% in the first cohort of 41 patients walked into in the EBMT/EULAR database to 8.7%. Additionally, of the 28 patients assigned to the transplant arm of the Autologous Stem cell Transplantation Internationally Scleroderma (ASTIS) trial, none have died to date. A comparable pattern has been noted in cases of multiple sclerosis (MS) [31].

5.5 Autoimmune diseases and autoimmunity post-bone marrow transplantation

BMT has been proposed as an alternative remedy for extreme autoimmune illnesses since it has the ability to both propagate and eradicate autoimmune disorders. We address whether persistent GVHD is an autoimmune disease in and of themselves in this interaction, examine the research about autoimmune diseases that have been reported in individuals after bone marrow transplantation, and outline the autoimmune characteristics of the post-BMT state. A common post-BMT consequence, chronic GVHD has symptomatic and pathologic traits with autoimmune illnesses including scleroderma and Sjogren's syndrome [32]. The thymic destruction caused by acute GVHD may be a contributing factor to the immunodeficiency and autoimmunity that characterize chronic GVHD, even if the pathophysiology of this condition is still unclear. Syngeneic GVHD is a related disease that arises from a disconnect among autoreactive and autoregulatory. Other autoimmune disorders have also been linked to post-BMT patients; among the most prevalent ones are immunological cytopenias, myasthenia gravis, hyperthyroidism, and hypothyroidism [33]. These illnesses are distinct in their disease progression (myasthenia gravis and thymic pathology are not associated), evaluation (hyperthyroidism indications may be mistakenly associated with other circumstances), and prognosis (post-BMT autoimmune cytopenias may be fatal and medically unresponsive), despite the fact that they also happen outdoors of the post-BMT setting. However, a plethora of other autoimmune diseases mostly given as case reports—have been documented subsequent to BMT. When it comes to the system of post-BMT autoimmunity, the majority of instances (either chronic GVHD or particular illnesses) can be explained by the immunologic disparities that characterize the post-BMT environment, whereas the minority of instances result from donor-related transmission of pathogenic lymphocytes or their precursors. Genetic genetic predisposition, an environmental factor like CMV, and the characteristics

of the donor, who may help create microchimerism and subsequently persistent GVHD and its attendant autoimmune symptoms, are the elements that may expose a person to autoimmunity formation post-BMT [34].

5.6 The role of microRNA in rheumatoid arthritis and other autoimmune diseases

A class of non-coding RNA molecules known as microRNAs (miRNAs) is involved in several critical physiological and growth-related processes. Up to one-third of all human protein-encoding genes are expected to be impacted by miRNAs, which modify the post-transcriptional transcription of many target genes [38]. It was just recently discovered that miRNA plays a role in both the immune system's two types of immunity. A specific instance of a chronic inflammatory disease where miRNAs may act as biomarkers for both the process of inflammation and the possibility of a response to treatment is rheumatoid arthritis. miRNAs in this disease regulate the inflammatory process within the joints. The studies that led to the identification of miRNAs, their biogenesis and mechanism of action, and the various ways that miRNAs influence inflammatory and immunological responses are all covered in this overview. The possible effects of miRNA biology in the development of rheumatoid arthritis and other autoimmune illnesses are discussed as we wrap up [39].

Chapter 6
Conclusion

6. Conclusion

In conclusion, autoimmune bone diseases present significant challenges in diagnosis, treatment, and management, owing to their complex etiology and diverse clinical manifestations. The intricate interplay between the immune system and bone metabolism underscores the need for comprehensive understanding and targeted therapeutic approaches. Despite advancements in research, many aspects of these diseases remain elusive, necessitating continued exploration to unravel their underlying mechanisms. The development of prospective therapeutics holds promise in revolutionizing the management of autoimmune bone diseases. Therapeutic approach for autoimmune diseases include physical therapy, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying anti-inflammatory drugs (DMARDs), anticytokine therapies, inhibition of intracellular-signaling pathways, costimulation inhibition, biological inhibitors of T cell. Targeted biologic agents, immunomodulatory drugs, and regenerative therapies offer novel avenues for intervention, aiming to suppress pathological immune responses while promoting bone repair and regeneration. Furthermore, personalized treatment strategies tailored to individual patient profiles may enhance efficacy and minimize adverse effects. Autoimmune bone diseases present diagnostic and treatment challenges due to their complexity and variability in symptoms, requiring comprehensive interdisciplinary approaches for effective management.

Chapter 7
Reference

References

1. Lerner A, Jeremias P, Matthias T. The world incidence and prevalence of autoimmune diseases is increasing. Int J Celiac Dis (2015) 3(4):151–5. doi: 10.12691/ijcd-3-4-8

2. Chang C. Unmet needs in the treatment of autoimmunity: from aspirin to stem cells. Autoimmun Rev (2014) 13(4–5):331–46. doi:10.1016/j.autrev.2014.01.052

3. Christakos S, Ajibade DV, Dhawan P, Fechner AJ, Mady LJ. Vitamin D: metabolism. Endocrinol Metab Clin North Am (2010) 39(2):243–53. doi:10.1016/j.ecl.2010.02.002

4. Pike JW, Meyer MB. The vitamin D receptor: new paradigms for the regulation of gene expression by 1,25-dihydroxyvitamin D(3). Endocrinol Metab Clin North Am (2010) 39(2):255–69. doi:10.1016/j.ecl.2010.02.007

5. Heikkinen S, Vaisanen S, Pehkonen P, Seuter S, Benes V, Carlberg C. Nuclear hormone 1alpha,25-dihydroxyvitamin D3 elicits a genome-wide shift in the locations of VDR chromatin occupancy. Nucleic Acids Res (2011) 39(21):9181–93. doi:10.1093/nar/gkr654

6. Evans RM, Mangelsdorf DJ. Nuclear receptors, RXR, and the big bang. Cell (2014) 157(1):255–66. doi:10.1016/j.cell.2014.03.012

7. Meyer MB, Goetsch PD, Pike JW. VDR/RXR and TCF4/beta-catenin cistromes in colonic cells of colorectal tumor origin: impact on c-FOS and c-MYC gene expression. Mol Endocrinol (2012) 26(1):37–51. doi:10.1210/me.2011-1109

8. Handel AE, Sandve GK, Disanto G, Berlanga-Taylor AJ, Gallone G, Hanwell H, et al. Vitamin D receptor ChIP-seq in primary CD4+ cells: relationship to serum 25-hydroxyvitamin D levels and autoimmune disease. BMC Med (2013) 11:163. doi:10.1186/1741-7015-11-163

9. Carmeliet G, Dermauw V, Bouillon R. Vitamin D signaling in calcium and bone homeostasis: a delicate balance. Best Pract Res Clin Endocrinol Metab (2015) 29(4):621–31. doi:10.1016/j.beem.2015.06.001

10. Ellman P, Anderson KH. Calciferol in tuberculous peritonitis with disseminated tuberculosis. Br Med J (1948) 1(4547):394. doi:10.1136/bmj.1.4547.394

11. Bhalla AK, Amento EP, Clemens TL, Holick MF, Krane SM. Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab (1983) 57(6):1308–10. doi:10.1210/jcem-57-6-1308

12. Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science (1983) 221(4616):1181–3. doi:10.1126/science.6310748

13. Lemire JM, Archer DC. 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest (1991) 87(3):1103–7. doi:10.1172/JCI115072

14. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A (1996) 93(15):7861–4. doi:10.1073/pnas.93.15.7861

15. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr (1998) 128(1):68–72.

16. Zwerina K, Baum W, Axmann R, Heiland GR, Distler JH, Smolen J, et al. Vitamin D receptor regulates TNF-mediated arthritis. Ann Rheum Dis (2011) 70(6):1122–9. doi:10.1136/ard.2010.142331

17. Zhang H, Wu H, Liu L, Li H, Shih DQ, Zhang X. 1,25-dihydroxyvitamin D3 regulates the development of chronic colitis by modulating both T helper (Th)1 and Th17 activation. APMIS (2015) 123(6):490–501. doi:10.1111/apm.12378

18. Cantorna MT, Munsick C, Bemiss C, Mahon BD. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr (2000) 130(11):2648–52.

19. Mathieu C, Laureys J, Sobis H, Vandeputte M, Waer M, Bouillon R. 1,25-Dihydroxyvitamin D3 prevents insulitis in NOD mice. Diabetes (1992) 41(11):1491–5. doi:10.2337/diabetes.41.11.1491

20. Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R. Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia (1994) 37(6):552–8. doi:10.1007/BF00403372

21. Lemire JM, Ince A, Takashima M. 1,25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/l mice. Autoimmunity (1992) 12(2):143–8. doi:10.3109/08916939209150321

22. Simpson S Jr, Blizzard L, Otahal P, Van der Mei I, Taylor B. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry (2011) 82(10):1132–41. doi:10.1136/jnnp.2011.240432

23. Mohr SB, Garland CF, Gorham ED, Garland FC. The association between ultraviolet B irradiance, vitamin D status and incidence rates of type 1 diabetes in 51 regions worldwide. Diabetologia (2008) 51(8):1391–8. doi:10.1007/s00125-008-1061-5

24. Szilagyi A, Leighton H, Burstein B, Xue X. Latitude, sunshine, and human lactase phenotype distributions may contribute to geographic patterns of modern disease: the inflammatory bowel disease model. Clin Epidemiol (2014) 6:183–98. doi:10.2147/CLEP.S59838

25. Dobson R, Giovannoni G, Ramagopalan S. The month of birth effect in multiple sclerosis: systematic review, meta-analysis and effect of latitude. J Neurol Neurosurg Psychiatry (2013) 84(4):427–32. doi:10.1136/jnnp-2012-303934

26. Torkildsen O, Grytten N, Aarseth J, Myhr KM, Kampman MT. Month of birth as a risk factor for multiple sclerosis: an update. Acta Neurol Scand (2012) 126(Supp. 195):58–62. doi:10.1111/ane.12040

27. Song GG, Bae SC, Lee YH. Association between vitamin D intake and the risk of rheumatoid arthritis: a meta-analysis. Clin Rheumatol (2012) 31(12):1733–9. doi:10.1007/s10067-012-2080-7

28. Zipitis CS, Akobeng AK. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch Dis Child (2008) 93(6):512–7. doi:10.1136/adc.2007.128579

29. Dong JY, Zhang WG, Chen JJ, Zhang ZL, Han SF, Qin LQ. Vitamin D intake and risk of type 1 diabetes: a meta-analysis of observational studies. Nutrients (2013) 5(9):3551–62. doi:10.3390/nu5093551

30. Shen L, Zhuang QS, Ji HF. Assessment of vitamin D levels in type 1 and type 2 diabetes patients: results from meta-analysis. Mol Nutr Food Res (2016) 60(5):1059–67. doi:10.1002/mnfr.201500937

31. Duan S, Lv Z, Fan X, Wang L, Han F, Wang H, et al. Vitamin D status and the risk of multiple sclerosis: a systematic review and meta-analysis. Neurosci Lett (2014) 570:108–13. doi:10.1016/j.neulet.2014.04.021

32. Lin J, Liu J, Davies ML, Chen W. Serum vitamin D level and rheumatoid arthritis disease activity: review and meta-analysis. PLoS One (2016) 11(1):e0146351. doi:10.1371/journal.pone.0146351

33. Del Pinto R, Pietropaoli D, Chandar AK, Ferri C, Cominelli F. Association between inflammatory bowel disease and vitamin D deficiency: a systematic review and meta-analysis. Inflamm Bowel Dis (2015) 21(11):2708–17. doi:10.1097/MIB.0000000000000546

34. Lu C, Yang J, Yu W, Li D, Xiang Z, Lin Y, et al. Association between 25(OH)D level, ultraviolet exposure, geographical location, and inflammatory bowel disease activity: a systematic review and meta-analysis. PLoS One (2015) 10(7):e0132036. doi:10.1371/journal.pone.0132036

35. Sadeghian M, Saneei P, Siassi F, Esmaillzadeh A. Vitamin D status in relation to Crohn's disease: meta-analysis of observational studies. Nutrition (2016) 32(5):505–14. doi:10.1016/j.nut.2015.11.008

36. Feng R, Li Y, Li G, Li Z, Zhang Y, Li Q, et al. Lower serum 25 (OH) D concentrations in type 1 diabetes: a meta-analysis. Diabetes Res Clin Pract (2015) 108(3):e71–5. doi:10.1016/j.diabres.2014.12.008

37. Sahebari M, Nabavi N, Salehi M. Correlation between serum 25(OH)D values and lupus disease activity: an original article and a systematic review with meta-analysis

focusing on serum VitD confounders. Lupus (2014) 23(11):1164–77. doi:10.1177/0961203314540966

38. Hiraki LT, Arkema EV, Cui J, Malspeis S, Costenbader KH, Karlson EW. Circulating 25-hydroxyvitamin D level and risk of developing rheumatoid arthritis. Rheumatology (Oxford) (2014) 53(12):2243–8. doi:10.1093/rheumatology/keu276

39. Tizaoui K, Kaabachi W, Hamzaoui A, Hamzaoui K. Association between vitamin D receptor polymorphisms and multiple sclerosis: systematic review and meta-analysis of case-control studies. Cell Mol Immunol (2015) 12(2):243–52. doi:10.1038/cmi.2014.47